Theravance Biopharma (NASDAQ: TBPH) announced the initiation of a Phase 2b study of velusetrag (TD-5108), an investigational drug for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Theravance Biopharma Announces Initiation of Phase 2b Study of Velusetrag (TD-5108) for the Treatment of GastroparesisMarch 12, 2015 4:05 PM Theravance Biopharma (TBPH) Misses Q4 EPS by 32cMarch 10, 2015 4:48 PM Form 8-K Theravance Biopharma, For: Mar 10March 10, 2015 4:45 PM